|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||140.23 - 142.55|
|52 Week Range||109.24 - 166.07|
|Beta (3Y Monthly)||0.91|
|PE Ratio (TTM)||54.99|
|Forward Dividend & Yield||0.73 (0.52%)|
|1y Target Est||181.00|
PA) and Medidata Solutions, Inc. ("Medidata") (MDSO) announced that Medidata stockholders have approved on August 16, 2019 the proposed acquisition of Medidata by Dassault Systèmes. At a special meeting of Medidata stockholders held on August 16, 2019, 78% of Medidata’s total outstanding common stock voted in favor of the proposed acquisition and 99% of shares voted were in favor of the proposed acquisition.
Vélizy-Villacoublay, August 5, 2019 DISCLOSURE OF TRADING IN OWN SHARES(Repurchase program decided by the General Meeting of Shareholders of May 23, 2019) Issuer: Dassault.
Declaration of the number of outstanding shares and voting rightsas of July 31, 2019 Vélizy-Villacoublay (France) August 5, 2019 – Dassault Systèmes (Euronext Paris: #13065,.
Availability of Dassault Systèmes’ 2019 Half-Year Financial Report (IFRS Half-Year Consolidated Condensed Financial Statements) Vélizy-Villacoublay, France – July 25,.
Dassault Systèmes and SATS Create World’s First Virtual Kitchen for In-Flight Catering Production Dassault Systèmes collaborated with SATS, Asia’s leading food solutions and.
Dassault Systèmes Reports First Half Revenue and EPS Growth Up Double-digits, Reaffirms 2019 Financial Objectives VÉLIZY-VILLACOUBLAY, France — July 24, 2019 — Dassault.
Dassault Aviation Advances its Next Generation Enterprise Platform: 3DEXPERIENCE for All Programs Dassault Aviation will rely on six Dassault Systèmes industry solution.
In 2002 Bernard Charlès was appointed CEO of Dassault Systèmes SE (EPA:DSY). This analysis aims first to contrast CEO...
Half-year statement of the Liquidity contract between Dassault Systèmes and Oddo BHF SCA Vélizy-Villacoublay, France – July 17, 2019 — Dassault Systèmes (Euronext Paris:.
Update of the liquidity contract Vélizy-Villacoublay (France) – July 17, 2019 — Dassault Systèmes (Euronext Paris: #13065, DSY.PA), “The 3DEXPERIENCE Company”, announces that.
DASSAULT SYSTEMES TO PUBLISHITS SECOND QUARTER 2019 RESULTS,WEBCAST AND CONFERENCE CALL ON JULY 24th 2019 VÉLIZY-VILLACOUBLAY, France — July 11th, 2019 — Dassault.
Declaration of the number of outstanding shares and voting rightsas of June 30, 2019 Vélizy-Villacoublay (France) July 8, 2019 – Dassault Systèmes (Euronext Paris: #13065,.
Today we'll evaluate Dassault Systèmes SE (EPA:DSY) to determine whether it could have potential as an investment...
Dassault Systèmes Named Key Supplier by Groupe PSA for its Digital Transformation Dassault Systèmes becomes the first and only software provider today to be recognized as.
Dassault Systèmes Continues to Demonstrate Its Commitment to Life Sciences for Patient Experience by Investing in BioSerenity BioSerenity, developer of solutions dedicated.
NEW YORK, June 12, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Medidata Solutions (NASDAQ: MDSO) on behalf of.
shares traded lower Wednesday after it agreed a takeover offer from France's Dassault Systemes SE at a discount to its current market value. Dassault said it would pay $92.25 for each Medidata share in a deal that values the New York-based group at $5.8 billion. "Today marks a significant milestone for the Life Sciences industry and the value of the virtual world to address the complexity of developing personalized medicine and patient-centric experiences," said Dassault CEO Bernard Charles.
(Bloomberg) -- French technology company Dassault Systemes SE agreed to buy Medidata Solutions Inc., a software firm that analyzes clinical trials, for $5.7 billion to bolster its offerings to the pharmaceutical industry.The record deal will allow Dassault to offer drugmakers a complete set of services and ride a shift toward personalized medicine, in which research and tools are tailored to individual patient profiles, generating the need to analyze vast amounts of data.Health is becoming a crucial market for Dassault, which also creates 3D design software, said Pascal Daloz, the company’s chief financial officer. Medidata offers clients wearable sensors that help track patients’ health in real life and biomarker analysis to select which ones may best respond to drugs. It estimates that 13 of the top 15 medicines sold last year relied on its technology.“This is by far the largest acquisition we’ve ever made,” Daloz said on a conference call, highlighting Dassault’s interest in the health market.Drugmakers’ CostsThe all-cash transaction values Medidata at $92.25 a share -- 17% more than Medidata’s closing price on April 18, the last trading day before Bloomberg reported Dassault’s interest in the New York-based company. Medidata shares were down 3.5% to $91.45 at 9:59 a.m. in New York. Dassault fell 1.5% to 134.45 euros in Paris.The deal is expected to close in the final quarter of 2019 and start boosting earnings as early as 2020, the companies said in a statement.Drugmakers faced with rising development costs are outsourcing many parts of their research and development efforts, using specialized providers of services and technology.Medidata counts most of the biggest drug companies in the world as customers, according to supply-chain data compiled by Bloomberg. It provides a cloud-based subscription service that helps medical device, diagnostic and pharmaceutical companies manage and analyze clinical trials. Its revenue more than doubled from 2013 to 2018, when it brought in $635.7 million.Dassault, with a market value of 36 billion euros ($41 billion), offers software and services for industries ranging from aerospace and defense to consumer goods. The life sciences business counts many major pharma companies among its clients.The planned acquisition, endorsed by both boards, marks the first time the French company has resorted to external funding, according to Daloz. Dassault will finance the takeover with a 1 billion-euro loan, a 3 billion-euro bridge-to-loan facility and available cash.(Updates with Dassault shares in sixth paragraph.)\--With assistance from Liana Baker, Geraldine Amiel and Marie Mawad.To contact the reporters on this story: Ed Hammond in New York at email@example.com;Ruth David in London at firstname.lastname@example.org;Manuel Baigorri in Hong Kong at email@example.comTo contact the editors responsible for this story: Elizabeth Fournier at firstname.lastname@example.org, ;Giles Turner at email@example.com, Jeff Sutherland, Thomas MulierFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
WILMINGTON, Del., June 12, 2019 -- Rigrodsky & Long, P.A.: Do you own shares of Medidata Solutions, Inc. (NASDAQ GS: MDSO)? Did you purchase any of your shares prior to.
U.S. stock futures declined on Wednesday as optimism faded over a near-term trade deal between Washington and Beijing and Wall Street awaited a reading on U.S. inflation. Contracts tied to the Dow Jones Industrial Average fell 71 points, futures for the S&P 500 declined 8.65 points, and Nasdaq futures were down 37 points. Donald Trump said Tuesday he wouldn't agree to a trade deal unless China agrees to four or five "major points" that the president didn't specify.
(Bloomberg) -- Dassault Systemes SE, a maker of industrial design software, agreed to buy Medidata Solutions Inc. for $5.7 billion to gain a foothold in the fast-growing market for clinical trial technology.The deal pushes the French company further beyond its design roots into data processing and business analysis. Medidata’s software analyzes pharmaceutical and biotech trials for some of the world’s biggest drugmakers including Sanofi SA, Pfizer Inc. and AstraZeneca Plc.“This is by far the largest acquisition we’ve ever made,” Pascal Daloz, chief financial officer of Dassault Systemes, said on a conference call. He said health is becoming a crucial market for the company, whose customers are mostly in aerospace, defense and consumer goods.The all-cash deal values New York-based Medidata at $92.25 a share, 17% above its closing price on April 18, the last trading day before Bloomberg reported Dassault Systemes’ interest in the company. Medidata stock fell 4.4% to $90.60 in premarket trading.Shares in Dassault Systemes, which has a market value of 36 billion euros ($41 billion) and annual sales of 3.5 billion euros last year, fell as much as 3% before recouping some of the decline to trade down 1% at 11:31 a.m. in Paris.Personalized MedicineMedidata offers clients wearable sensors that help track patient health and biomarker analysis to select which patients may best respond to certain drugs. It estimates that 13 of the top 15 medicines sold last year relied on its technology, as the healthcare industry shifts towards personalized medicine and the targeting of individual patient profiles.President Donald Trump’s protectionist trade agenda hasn’t reduced the appetite of European companies for U.S. takeovers. In fact their appeal has been growing, potentially turning the tables after years in which Europe was mostly a target for U.S. acquirers.French advertising group Publicis Groupe SA announced its biggest ever takeover in April, a $4.4 billion deal for U.S.-based Alliance Data Systems Corp.’s digital marketing unit Epsilon.The Medidata deal is expected to close in the final quarter of 2019 and start boosting earnings as early as 2020, the companies said in a statement. Dassault Systemes will finance it with a 1 billion-euro loan, a 3 billion-euro bridge-to-loan facility and available cash. It’s the first time the French company has resorted to external funding, Daloz said.(Adds Medidata premarket share price in fourth paragraph.)\--With assistance from Liana Baker, Manuel Baigorri, Ruth David, Ed Hammond and Marthe Fourcade.To contact the reporters on this story: Marie Mawad in Paris at firstname.lastname@example.org;Geraldine Amiel in Paris at email@example.comTo contact the editors responsible for this story: Giles Turner at firstname.lastname@example.org, Thomas Pfeiffer, Frank ConnellyFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Dassault Systemes SE on Wednesday announced a definite agreement for U.S. technology group Medidata Solutions Inc. , in an agreement valued at $5.8 billion. Under terms of the all-cash deal, the French technology group will offer $92.25 for each share of Medidata, whose shares closed at $94.75 a share on Tuesday. The transaction was unanimously approved by the boards of directors of both companies.